Taken together, the results confirm that directly targeting YAP1/SP1 and miR-375 would be a potential therapeutic strategy to reverse multiple chemoresistance in CRC through the regulation of the Hippo signaling pathway. Here, YAP1 is linked to colorectal carcinoma.